{"analyses":[{"ciLowerLimit":"0.308","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.020","estimateComment":"Hazard ratio was based on an unstratified Cox proportional hazard regression model and treatment as a factor in the model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.620","pValueComment":"P-value is from an unstratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.789","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of full range was not estimable due to low number of participants with the event.","groupId":"OG000","lowerLimit":"8.31","upperLimit":"NA","value":"12.9"},{"comment":"The upper limit of full range was not estimable due to low number of participants with the event.","groupId":"OG001","lowerLimit":"9.00","upperLimit":"NA","value":"18.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML) or relapse after CR or PR (participants with HR MDS/CMML). Disease responses for HR MDS or CMML are based on the Modified IWG Response Criteria for MDS and for low-blast AML on the Revised IWG Response Criteria for AML.CR for HR MDS or CMML≤5% myeloblasts with normal maturation of all cell lines in the bone marrow,≥11 g/dL Hgb,≥100\\*10\\^9/L pl,≥1.0\\*10\\^9/L neutrophils;0% blasts in peripheral blood.CR for low-blast AML:morphologic leukemia-free state,neutrophils of\\<1.0\\*10\\^9/L;pl of≥100\\*10\\^9/L,transfusion independence,no residual evidence of extramedullary leukemia.CRi for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\\<1.0\\*10\\^9/L) or thrombocytopenia (pl\\<100\\*10\\^9/L).","dispersionType":"Full Range","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"REP included all participants who received at least 1 dose of study drug and had a Baseline and at least 1 postbaseline disease assessment. Data is reported for the responders with complete remission.","reportingStatus":"POSTED","timeFrame":"From date of randomization until CR (up to approximately 5 years)","title":"Duration of Complete Remission (CR)","type":"SECONDARY","unitOfMeasure":"months"}